Product logins

Find logins to all Clarivate products below.


Multiple myeloma remains an incurable hematological malignancy despite the availability of several treatments. Resistance to therapy is the primary challenge associated with the disease’s relapse and recurrence, especially in elderly patients. The foremost goal in the third-line treatment of multiple myeloma is extending the patient’s survival. The mainstays of treatment have been agents that affect the immune system, such as Bristol Myers Squibb’s Revlimid and Pomalyst / Imnovid used with the generic corticosteroid dexamethasone. The prescribing of proteasome inhibitors such as Amgen / Ono Pharmaceutical’s Kyprolis and Takeda’s Ninlaro, along with the emergence of novel drugs such as Janssen’s Darzalex, Sanofi’s Sarclisa, and Karyopharm’s Xpovio, is having an impact on treatment choices in the third-line setting. However, in the absence of a uniform treatment regimen, the choice of third-line therapy for multiple myeloma remains fragmented.

QUESTIONS ANSWERED

  • What treatment drivers and goals are most likely to influence the choice of third-line therapy or regimen in multiple myeloma?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key clinical drug attributes for this patient population?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs across clinical attributes and price are acceptable to surveyed hematologist-oncologists for a new therapy or regimen for third-line multiple myeloma?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. and 30 European hematologist-oncologists fielded in May 2021

Key companies: Janssen, Bristol Myers Squibb, Takeda, Amgen / Ono Pharmaceutical, Sanofi, Karyopharm Therapeutics.

Key drugs: Darzalex, Revlimid, Ninlaro, Kyprolis, Pomalyst / Imnovid, Sarclisa, Xpovio

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Human Immunodeficiency Virus – Landscape & Forecast – Disease Landscape & Forecast (G7)
The HIV therapy market is undergoing significant transformation, driven by innovative ARVs and evolving treatment strategies. The market is crowded with many approved ARVs, including STRs such as…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…